Sign Out
Glycaemic control: Victoza is indicated for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise: as monotherapy; in addition to other medicinal products for the treatment of diabetes.
Prevention of cardiovascular events: Victoza is indicated to prevent Major Adverse Cardiovascular Events (MACE: cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus at high cardiovascular risk, as an adjunct to standard of care therapy (see Pharmacology: Pharmacodynamics: Clinical efficacy and safety: Cardiovascular evaluation under Actions).
For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see Precautions, Interactions and Pharmacology: Pharmacodynamics under Actions.
